Cho, SY, Jeong, SJ, Lee, S, Kim, J, Lee, SH, Choo, MS, Oh, SJ. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson’s disease: s double-blind, randomized placebo-controlled trial (Parkinson’s Disease Overactive bladder Mirabegron, PaDoMi Study). Neurourol Urodyn 2021; 40(1): 286–294.CrossRefGoogle ScholarPubMed

Madan, A, Brown, T, Ray, S, Agarwal, P, Roy-Faderman, I, Burdick, D. A novel trial of mirabegron and behavioral modification including pelvic floor exercise for overactive bladder in Parkinson’s disease (MAESTRO). Cureus 2022; 14(11): e31818.Google ScholarPubMed

Moussa, M, Chakra, MA, Dabboucy, B, Fares, Y, Dellis, A, Papatsoris, A. The safety and effectiveness of mirabegron in Parkinson’s disease patients with overactive bladder: a randomized controlled trial. Scand J Urol 2022; 56(1): 66–72.CrossRefGoogle ScholarPubMed

Peyronnet, B, Vurture, G, Palma, JA, Malacarne, DR, Feigin, A, Sussman, RD, Biagioni, MC, Palmerola, R, Gilbert, R, Rosenblum, N, Frucht, S, Kaufmann, H, Nitti, VW, Brucker, BM. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord 2018; 57: 22–26.CrossRefGoogle ScholarPubMed

AHFS Drug Information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 29 December 2022 via www.medicinescomplete.com.Google Scholar

Eltink, C, Lee, J, Schaddelee, M, Zhang, W, Kerbusch, V, Meijer, J, van Marle, S, Grunenberg, N, Kowalski, D, Drogendijk, T, Moy, S, Iitsuka, H, van Gelderen, M, Matsushima, H, Sawamoto, T. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther 2012; 50(11): 838–850.CrossRefGoogle ScholarPubMed

Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 29 December 2022 via www.medicinescomplete.com.Google Scholar

Matta, R, Gomes, T, Juurlink, D, Jarvi, K, Herschorn, S, Nam, RK. Receipt of overactive bladder drugs and incident dementia: a population-based case–control study. Eur Urol Focus 2022; 8(5): 1433–1440.CrossRefGoogle ScholarPubMed

Mirabegron. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 29 December 2022 via www.medicinescomplete.com.Google Scholar

Mirabegron. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 29 December 2022 via www.micromedexsolutions.com.Google Scholar

Nunzio, CDE, Nacchia, A, Gravina, C, Turchi, B, Gallo, G, Trucchi, A, Giacomo, FDI, Disabato, G, Franco, A, Rovesti, L, Lombardo, R, Cicione, A, Tubaro, A. Adverse events related to antimuscarinics and beta-3-agonist: “real-life” data from the Eudra-Vigilance database. Minerva Urol Nephrol 2022; 74(6): 761–779.Google ScholarPubMed

Summary of product characteristics – Betmiga 25 mg prolonged-release tablets. Astellas Pharma Ltd. Electronic Medicines Compendium: Betmiga 25 mg prolonged-release tablets – summary of product characteristics (SmPC) – (emc). Accessed on 29 December 2022 via www.medicines.org.uk.Google Scholar